Cipla Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cipla şirketinin toplam hissedar öz sermayesi ₹284.6B ve toplam borcu ₹1.6B olup, bu da borç-öz sermaye oranını 0.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹346.6B ve ₹62.0B dir. Cipla 'in FAVÖK'ü ₹57.3B faiz karşılama oranı -36.5 dur. Şirketin ₹87.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.6%

Borç/özkaynak oranı

₹1.62b

Borç

Faiz karşılama oranı	-36.5x
Nakit	₹87.08b
Eşitlik	₹284.56b
Toplam yükümlülükler	₹62.00b
Toplam varlıklar	₹346.55b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CIPLA 'nin kısa vadeli varlıkları ( ₹209.5B ) kısa vadeli yükümlülüklerini ( ₹54.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: CIPLA şirketinin kısa vadeli varlıkları ( ₹209.5B ) uzun vadeli yükümlülüklerini ( ₹7.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CIPLA şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CIPLA 'nin borç/öz sermaye oranı son 5 yılda 22.4% seviyesinden 0.6% seviyesine düştü.

Borç Kapsamı: CIPLA 'nin borcu işletme nakit akışı ( 2775% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: CIPLA ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Cipla Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Cipla Limited Announces Executive Changes

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Cipla Limited Announces Resignation of Kedar Upadhye from the Position of Global Chief Financial Officer

Cipla Limited and Cipla USA, Inc. Receive Final Approval for Lanreotide Injection

Cipla Limited (NSEI:CIPLA) entered into an agreement to acquire 33% stake in Clean Max Auriga Power LLP for INR 60 million.

Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

Cipla Receives Final Approval for Generic Version of Sunovion Pharmaceuticals, Inc.'S Brovana® (Arformoterol Tartrate Inhalation Solution 15 Mcg/ 2Ml)

Roche India and Cipla Limited Announces First Batch of the Antibody Cocktail

Cipla Limited Announces Commercialization of Polymerase Chain Reaction (RT-PCR) Test Kit `ViraGen' for COVID-19 in India, in Partnership with Ubio Biotechnology Systems Pvt. Ltd

Cipla Limited Recommends Dividend for the Year 2020-21

Cipla Limited's Subsidiary, Cipla Gulf Fz Lcc Expands Its Partnership with Alvotech for the Marketing and Distribution of Four Biosimilar Medicines in Australia and New Zealand

Cipla Limited Announces Partnership with the Premier Medical Corporation Private Limited for Commercialisation of the Rapid Antigen Test Kits for COVID-19 in India

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID (Lenalidomide) with Cipla

Cipla Limited Launches Covi-G for COVID-19 Rapid Antibody Detection

Cipla Limited Receives Final Approval for Generic Version of Biogen Idec Inc.'S Tecfidera® (Dimethyl Fumarate Dr Capsules 120Mg, 240Mg and 120Mg/240Mg Starter Pack)

Cipla Limited Receives Final Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Dimethyl Fumarate DR Capsules Starter Pak

Cipla Limited Launches Generic Version of Broad-Spectrum Anti-Viral Drug Remdesivir (Branded Cipremi), to Be Used on Critically Ill Covid Patients in the Hospitals

Cipla Limited to Report Q3, 2021 Results on Feb 05, 2021

Cipla Limited to Report Q1, 2021 Results on Aug 07, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin